TipRanks
Eupraxia Pharmaceuticals (EPRX)
NASDAQ:EPRX
US Market
EPRX
Eupraxia Pharmaceuticals
RESEARCH TOOLSreports

Eupraxia Pharmaceuticals (EPRX) Stock News & Sentiment

46 Followers
Brandon Folkes Reiterates Buy on EP-104GI as New 52-Week Data Reinforce Once-Yearly Dosing Upside; Price Target Unchanged at $11
Premium
Ratings
Brandon Folkes Reiterates Buy on EP-104GI as New 52-Week Data Reinforce Once-Yearly Dosing Upside; Price Target Unchanged at $11
7d ago
EPRX
EPIRUS Therapeutics: Buy Rating Reiterated on EP-104GI’s Emerging Clinical Profile and Upcoming Phase 2b Catalyst; $16 Price Target Unchanged
Premium
Ratings
EPIRUS Therapeutics: Buy Rating Reiterated on EP-104GI’s Emerging Clinical Profile and Upcoming Phase 2b Catalyst; $16 Price Target Unchanged
8d ago
EPRX
EP-104GI’s Strong 52-Week EoE Data and Clean Safety Profile Underpin Buy Rating Ahead of Pivotal Phase IIb Readout
Premium
Ratings
EP-104GI’s Strong 52-Week EoE Data and Clean Safety Profile Underpin Buy Rating Ahead of Pivotal Phase IIb Readout
8d ago
EPRX
Eupraxia Pharmaceuticals Posts Strong 52-Week EoE Data for EP-104GI in RESOLVE Trial
Premium
Company Announcements
Eupraxia Pharmaceuticals Posts Strong 52-Week EoE Data for EP-104GI in RESOLVE Trial
8d ago
6K
EPRX
Eupraxia Pharmaceuticals Moves Up to Nasdaq Global Select Market and Ramps Investor Outreach
Premium
Company Announcements
Eupraxia Pharmaceuticals Moves Up to Nasdaq Global Select Market and Ramps Investor Outreach
30d ago
6K
EPRX
Eupraxia Therapeutics: Upcoming RESOLVE Trial Readouts and Symptom-Focused Data Strategy Underpin Buy Rating on EP-104GI
Premium
Ratings
Eupraxia Therapeutics: Upcoming RESOLVE Trial Readouts and Symptom-Focused Data Strategy Underpin Buy Rating on EP-104GI
1M ago
EPRX
Eupraxia Maintained at Buy as Analyst Reaffirms $16 Price Target on Differentiated EoE Opportunity
Premium
Ratings
Eupraxia Maintained at Buy as Analyst Reaffirms $16 Price Target on Differentiated EoE Opportunity
1M ago
EPRX
More EPRX News >

EPRX News on the Web

EPIRUS Therapeutics: Buy Rating Reiterated on EP-104GI’s Emerging Clinical Profile and Upcoming Phase 2b Catalyst; $16 Price Target Unchanged
TipRanks News
Bullish
Eupraxia Pharmaceuticals initiated with an Outperform at Wedbush
TipRanks News
Bullish
Eupraxia Pharma (EPRX): When Painful Swallowing Nearly Disappeared, Investors Took Notice
Insider Monkey
Neutral
Eupraxia Therapeutics: Buy Rating Reaffirmed on Advancing EoE Program and RESOLVE Phase 2b Readout, Price Target Maintained at $16
TipRanks News
Bullish
Buy Rating Reiterated on Eupraxia Ahead of Key EP-104GI Trial Data; $11 Price Target Maintained
TipRanks News
Bullish
Eupraxia Pharmaceuticals Overhauls Leadership and Operations Ahead of Key EoE Trial Milestone
TipRanks News
Neutral
Eupraxia chief scientific and operating officer Amanda Malone steps down
TipRanks News
Bullish
Eupraxia Pharmaceuticals Adds Veteran Drug Developers to Board as Pipeline Advances
TipRanks News
Neutral

News Score - Last 7 Days

Not enough data to generate a sentiment score
Media Buzz
This Week0 articles
Weekly Average3.25 articles
News Sentiment
Currently, no data available
See how Bullish or Bearish a stock is based on its recent media coverage.

This score is generated using a formula that combines Media Buzz and News Sentiment.

Media Coverage Analysis

The historical news coverage of this asset in the last three months.

FAQ

What is EPRX’s Media Buzz Sentiment?
Currently, no data Available
What is EPRX’s weekly average amount of articles?
In an average week, 3.25 articles about EPRX are published.
    What is EPRX’s News Sentiment?
    Currently, no data Available
    Healthcare Stocks that are Trending in the News
    XENEXenon
    ABTAbbott Laboratories
    BBIOBridgeBio Pharma
    BDXBecton Dickinson
    NVSNovartis
    Showing the stocks with the most bullish news sentiment over the past week